Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rubius Therapeutics Taps Dannielle Appelhans as Chief Operating Officer

07/29/2021 | 07:06am EDT

By Robb M. Stewart

Rubius Therapeutics Inc. Thursday named Dannielle Appelhans as chief operating officer to oversee corporate strategy and technical operations.

The appointment is effective Aug. 9, the clinical-stage biopharmaceutical company said.

Most recently, Ms. Appelhans was senior vice president of technical operations and chief technical officer at Novartis Gene Therapies, where she oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio Rubius. Prior to joining Novartis, she was a senior engagement manager at McKinsey & Co. in its pharmaceutical operations practice, and earlier in her career she held roles at Eli Lilly & Co.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

07-29-21 0906ET

All news about RUBIUS THERAPEUTICS, INC.
09/01Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global H..
GL
08/30Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
GL
08/30Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
CI
08/20RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
08/10RUBIUS THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides..
AQ
08/09RUBIUS THERAPEUTICS' : Q2 Net Loss Widens
MT
08/09RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
08/09RUBIUS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
08/09Rubius Therapeutics, Inc. Reports Earnings Results for the Second Quarter End..
CI
08/09RUBIUS THERAPEUTICS : Reports Second Quarter 2021 Financial Resultsáand Provides..
AQ
More news
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -197 M - -
Net cash 2021 121 M - -
P/E ratio 2021 -8,64x
Yield 2021 -
Capitalization 1 737 M 1 737 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 248
Free-Float 93,4%
Chart RUBIUS THERAPEUTICS, INC.
Duration : Period :
Rubius Therapeutics, Inc. Technical Analysis Chart | RUBY | US78116T1034 | MarketScreener
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 19,35 $
Average target price 30,17 $
Spread / Average Target 55,9%
EPS Revisions
Managers and Directors
Pablo J. Cagnoni President, Chief Executive Officer & Director
Jose Carmona Treasurer, Chief Financial & Accounting Officer
David R. Epstein Executive Chairman
Spencer Fisk Senior Vice President-Technical Operations
Christina Coughlin Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RUBIUS THERAPEUTICS, INC.154.94%1 737
GILEAD SCIENCES, INC.21.80%89 785
BIONTECH SE315.86%86 750
REGENERON PHARMACEUTICALS32.66%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-21.44%48 850